Major histocompatibility class I (MHC I) molecules bind peptides derived from a cell's
expressed genes and then transport and display this antigenic information on the cell …

Metastatic colorectal cancer (CRC) with a mismatch repair-deficiency (MMR-
D)/microsatellite instability-high (MSI-H) phenotype carries unique characteristics such as …

The clinical relevance of T cells in the control of a diverse set of human cancers is now
beyond doubt. However, the nature of the antigens that allow the immune system to …

The immune system deploys a multitude of innate and adaptive mechanisms not only to
ward off pathogens but also to prevent malignant transformation (“immune surveillance”) …

Immune checkpoint inhibitors (ICIs) targeting CTLA-4 and PD-1/PD-L1 to boost tumor-
specific T lymphocyte immunity have opened up new avenues for the treatment of various …

Tumours can escape T‐cell responses by losing major histocompatibility complex
(MHC)/human leucocyte antigen (HLA) class I molecules. In the early stages of cancer …

Deficient DNA mismatch repair (MMR) boosts the accumulation of frameshift mutations in
genes encompassing coding microsatellites (cMS). This results in the translation of proteins …

Purpose: DNA mismatch repair (MMR) deficiency is a hallmark of Lynch syndrome, the most
common inherited cancer syndrome. MMR-deficient cancer cells accumulate numerous …

Immune checkpoint blockade (ICB) has rapidly transformed the treatment paradigm for
various cancer types. Multiple single or combinations of ICB treatments have been approved …

T cell-mediated immune therapies have emerged as a promising treatment modality in
different malignancies including colorectal cancer (CRC). However, only a fraction of …